Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines ; volume:36 ; number:1 ; day:4 ; month:12 ; year:2017 ; pages:1-12 ; date:12.2017
Journal of experimental & clinical cancer research ; 36, Heft 1 (4.12.2017), 1-12, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
La Monica, Silvia
- Beteiligte Personen und Organisationen
-
Cretella, Daniele
Bonelli, Mara
Fumarola, Claudia
Cavazzoni, Andrea
Digiacomo, Graziana
Flammini, Lisa
Barocelli, Elisabetta
Minari, Roberta
Naldi, Nadia
Petronini, Pier Giorgio
Tiseo, Marcello
Alfieri, Roberta
SpringerLink (Online service)
- DOI
-
10.1186/s13046-017-0653-7
- URN
-
urn:nbn:de:1111-201802038465
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- La Monica, Silvia
- Cretella, Daniele
- Bonelli, Mara
- Fumarola, Claudia
- Cavazzoni, Andrea
- Digiacomo, Graziana
- Flammini, Lisa
- Barocelli, Elisabetta
- Minari, Roberta
- Naldi, Nadia
- Petronini, Pier Giorgio
- Tiseo, Marcello
- Alfieri, Roberta
- SpringerLink (Online service)
Ähnliche Objekte (12)
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC